CVS to Cover Lilly’s GLP-1 Medications, Expanding Access
CVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
Generating revenue from ideas involves innovation and market understanding. Learn how to monetize your concepts effectively.
17,831 articlesCVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
Four leading crypto assets trade below peaks as 2027 forecasts call for divergent upside. A $1,000 stake in each coul...
Intel overcame a tough 12 months to deliver a striking rebound. Analysts say the AI-led strategy and foundry expansio...
June opened with volatility as Nu Holdings faced a fresh downgrade and a leadership transition. This article breaks d...
As the new Fed chair shifts policy expectations, the chairman kevin warsh position hints at fewer rate cuts and possi...
NVIDIA and SK hynix announce a deeper partnership to secure high-bandwidth memory amid Jensen Huang's warning that th...
A recent SEC Form 4 shows a Teladoc executive sold roughly $71,000 worth of stock. This article breaks down what that...
Goldman Sachs and MORGAN STANLEY are jockeying for the lead left role in a pair of AI IPOs, a $7 billion opportunity ...
A 29-year-old AI investor has steered a hedge fund to $20 billion with a reported 1,000% return since inception. This...
Ripple's private business shows strong growth while XRP trades near a $1 price. This article builds a practical, evid...
Fox said it will acquire Roku in a $22 billion cash-and-stock deal, at $160 per Roku share. The transaction is slated...
Moderna has surged in 2026, outpacing its vaccine peers as pipeline progress and a leadership refresh reshape the com...